Protalix BioTherapeutics to Present at the 15th Annual BIO CEO & Investor Conference
February 05 2013 - 7:30AM
Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX) today
announced that Dr. David Aviezer, the Company's President and Chief
Executive Officer, will present at the 15th Annual BIO CEO and
Investor Conference on Tuesday, February 12, 2013 at 11:30 AM ET.
The conference is being held at the Waldorf Astoria Hotel in New
York City. A live webcast of the presentation will be
available at www.protalix.com on the event calendar page. A
replay will be archived and available after the conclusion of the
presentation for 30 days.
About the BIO CEO & Investor Conference
The 15th Annual BIO CEO & Investor Conference is the largest
independent investor conference focused on publicly-traded
biotechnology companies. This year's conference will feature
corporate presentations from more than 140 leading biotechnology
and pharmaceutical companies, Fireside Chats with industry leaders,
four Therapeutic Workshops and three Business Roundtables all
drawing from seasoned industry executives and analysts. New
this year, a special track of 25 high-caliber private companies
will be presenting at the event, and plenary sessions will address
timely business issues and industry trends. Attendees can
expect many opportunities to schedule one-on-one meetings as well
as numerous networking opportunities. The conference is
designed to foster an informative dialogue between institutional
investors and senior biotechnology executives about emerging and
current investment opportunities.
About Protalix BioTherapeutics,
Inc.
Protalix is a biopharmaceutical company focused on the
development and commercialization of recombinant therapeutic
proteins expressed through its proprietary plant cell based
expression system, ProCellEx®. Protalix's unique expression
system presents a proprietary method for developing recombinant
proteins in a cost-effective, industrial-scale manner.
Protalix's first approved product manufactured by ProCellEx,
ELELYSO™ (taliglucerase alfa), an enzyme replacement therapy for
the treatment of Gaucher disease, was approved for marketing by the
U.S. Food and Drug Administration in May 2012, and by Israel's
Ministry of Health in September 2012. Additional marketing
applications for taliglucerase alfa have been filed in other
countries. Protalix is partnered with Pfizer Inc. for
worldwide development and commercialization, excluding Israel,
where Protalix retains full rights. Protalix's development
pipeline also includes the following product candidates: PRX-102, a
modified version of the recombinant human alpha-GAL-A protein for
the treatment of Fabry disease; PRX-105, a pegylated recombinant
human acetylcholinesterase in development for several therapeutic
and prophylactic indications, a biodefense program and an
organophosphate-based pesticide treatment program; an
orally-delivered glucocerebrosidase enzyme that is naturally
encased in carrot cells, also for the treatment of Gaucher disease;
pr-antiTNF, a similar plant cell version of etanercept (Enbrel®)
for the treatment of certain immune diseases such as rheumatoid
arthritis, juvenile idiopathic arthritis, ankylosing spondylitis,
psoriatic arthritis and plaque psoriasis; and others.
CONTACT: Investor Contact
Marcy Nanus
The Trout Group, LLC
646-378-2927
mnanus@troutgroup.com
Media Contact
Kari Watson
MacDougall Biomedical Communications
781-235-3060
kwatson@macbiocom.com